Kyverna Therapeutics, Inc.

NASDAQ: KYTX · Healthcare · Biotechnology

PublicHQ Emeryville, CA · AlamedaCIK 0001994702Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 50DQ —GM —SS 50

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$161.3M

Employees

129

as of 2026-08-12

Market cap

$487.6M

as of 2026-08-12

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$161.3M-$161.3M2025

Operating income-$169.8M-$169.8M2025

Total assets$293.8M$293.8M2025

Liabilities$61.5M$61.5M2025

Equity$232.3M$232.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Kyverna Therapeutics, Inc.’s financial profile?

Kyverna Therapeutics, Inc. earned -$161.3M in FY2025 net income.

Peers · Healthcare

MapLight Therapeutics, Inc.——Nuvectis Pharma, Inc.——Eikon Therapeutics, Inc. Common Stock——Cabaletta Bio, Inc.——Rezolute, Inc.——PureTech Health plc——

Neighbors

Alameda →

Lam Research Corporation$18.4B85A Ross Stores, Inc.$22.8B79B+Block, Inc.$24.2B69B PG&E Corporation$24.9B70B Workday, Inc.$9.6B80B+Veeva Systems Inc.$3.2B81B+

Key facts

CEOWarner Biddle

SectorHealthcare

IndustryBiotechnology

HeadquartersEmeryville, CA

ExchangeNASDAQ: KYTX

Employees129

IPO date2024-02-09

Latest filings

8-K2026-08-11 10-Q2026-08-11 8-K2026-07-27 8-K2026-07-09 8-K2026-06-02 8-K2026-05-18 10-Q2026-05-12 8-K2026-05-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.